JP2019523633A5 - - Google Patents

Download PDF

Info

Publication number
JP2019523633A5
JP2019523633A5 JP2018556357A JP2018556357A JP2019523633A5 JP 2019523633 A5 JP2019523633 A5 JP 2019523633A5 JP 2018556357 A JP2018556357 A JP 2018556357A JP 2018556357 A JP2018556357 A JP 2018556357A JP 2019523633 A5 JP2019523633 A5 JP 2019523633A5
Authority
JP
Japan
Prior art keywords
cancer
disease
syndrome
inflammation
isolated peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018556357A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019523633A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/030100 external-priority patent/WO2017189988A1/en
Publication of JP2019523633A publication Critical patent/JP2019523633A/ja
Publication of JP2019523633A5 publication Critical patent/JP2019523633A5/ja
Pending legal-status Critical Current

Links

JP2018556357A 2016-04-29 2017-04-28 組織の損傷に関連した疾患及び障害を予防及び治療する組織保護ペプチド Pending JP2019523633A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662329743P 2016-04-29 2016-04-29
US62/329,743 2016-04-29
PCT/US2017/030100 WO2017189988A1 (en) 2016-04-29 2017-04-28 Tissue protective peptides for preventing and treating diseases and disorders associated with tissue damage

Publications (2)

Publication Number Publication Date
JP2019523633A JP2019523633A (ja) 2019-08-29
JP2019523633A5 true JP2019523633A5 (https=) 2020-06-18

Family

ID=60161215

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018556357A Pending JP2019523633A (ja) 2016-04-29 2017-04-28 組織の損傷に関連した疾患及び障害を予防及び治療する組織保護ペプチド

Country Status (5)

Country Link
US (1) US10864253B2 (https=)
EP (1) EP3448415A4 (https=)
JP (1) JP2019523633A (https=)
CN (1) CN109310741A (https=)
WO (1) WO2017189988A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3946547B1 (en) * 2019-03-26 2026-03-25 Pinova Therapeutics Inc. Devices and methods for delivering pharmaceutical compositions
KR20220009954A (ko) * 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법
JP2023506036A (ja) * 2019-12-13 2023-02-14 マサチューセッツ インスティテュート オブ テクノロジー 合成組織バリアおよびそれらの使用
TW202241927A (zh) * 2021-01-11 2022-11-01 大陸商四川好醫生攀西藥業有限責任公司 一類用於修復皮膚損傷或黏膜損傷之多肽及其應用
CN119908970B (zh) * 2025-01-23 2026-02-03 诺德溯源(广州)生物科技有限公司 一种用于改善女性更年期衰老的护肤组合物及其应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1479268A (en) 1973-07-05 1977-07-13 Beecham Group Ltd Pharmaceutical compositions
CH596313A5 (https=) 1975-05-30 1978-03-15 Battelle Memorial Institute
US4414147A (en) 1981-04-17 1983-11-08 Massachusetts Institute Of Technology Methods of decreasing the hydrophobicity of fibroblast and other interferons
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US5051448A (en) 1984-07-24 1991-09-24 The Mclean Hospital Corporation GABA esters and GABA analog esters
DE3676670D1 (de) 1985-06-26 1991-02-07 Cetus Corp Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
WO1994005332A2 (en) 1992-09-01 1994-03-17 Berlex Laboratories, Inc. Glycolation of glycosylated macromolecules
US5559103A (en) 1993-07-21 1996-09-24 Cytel Corporation Bivalent sialyl X saccharides
US5576423A (en) 1994-12-02 1996-11-19 Schering Corporation Antibodies to the slam protein expressed on activated T cells
IL114407A0 (en) * 1995-06-30 1995-10-31 Yeda Res & Dev Novel peptides and pharmaceutical compositions comprising them
IL114458A0 (en) * 1995-07-05 1995-11-27 Yeda Res & Dev Therapeutic preparations for treatment of T cell mediated diseases
PA8536201A1 (es) 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
AU2003228099A1 (en) * 2002-07-03 2004-01-23 Centro Cardiologico Monzino S.P.A.-Irccs Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair
KR20050083682A (ko) 2002-09-09 2005-08-26 워렌 파마슈티칼즈 인코포레이티드 내인성 에리트로포이에틴의 조직 보호 활성을 유지하는 장기 작용성 에리트로포이에틴
WO2005025606A1 (en) 2003-09-09 2005-03-24 Warren Pharmaceuticals, Inc. Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
BRPI0414887A (pt) 2003-09-29 2006-12-12 Warren Pharmaceuticals Inc E T métodos de tratamento, prevenção, retardo do inìcio ou redução dos efeitos de citocinas pró-inflamatórias em um mamìfero e de tratamento, prevenção, retardo do inìcio de uma condição associada com um efeito de citocinas pró-inflamatórias em um mamìfero, e, composição farmacêutica
US20090202618A1 (en) * 2003-11-24 2009-08-13 Yeda Research & Development Co. Ltd Dna vaccines encoding hsp60 peptide fragments for treating autoimmune diseases
EP1718158B1 (en) * 2004-01-28 2014-07-02 Andromeda Bio Tech Ltd. Hsp therapy in conjunction with a low antigenicity diet
WO2006083301A2 (en) 2004-06-17 2006-08-10 Medimmune, Inc. Immunogenic compositions comprising hmgb1 polypeptides
ZA200706016B (en) * 2004-12-21 2008-12-31 Musc Found For Res Dev Compositions and methods for promoting wound healing and tissue regeneration
TW200640485A (en) 2005-01-19 2006-12-01 Vaxinnate Corp Compositions of pathogen-associated molecular patterns and methods of use
HUE026444T2 (en) 2005-08-05 2016-05-30 Araim Pharmaceuticals Inc Tissue protection peptides and their use
CU23632A1 (es) * 2006-04-28 2011-02-24 Ct Ingenieria Genetica Biotech Métodos para la identificación de candidatos terapéuticos contra enfermedades causadas por flavivirus y moléculas antivirales.
WO2009094172A2 (en) 2008-01-22 2009-07-30 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
EP2703487B1 (en) 2011-04-26 2018-06-27 Genomix Co., Ltd. Peptide for inducing regeneration of tissue and use thereof
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
US9046530B2 (en) * 2011-12-02 2015-06-02 Board Of Regents, The University Of Texas System Methods and compositions for chlamydial antigens as reagents for diagnosis of tubal factor infertility and chlamydial infection
HK1223298A1 (zh) 2013-07-17 2017-07-28 阿拉伊姆药品公司 预防和治疗组织损伤相关疾病和病症的组织保护肽和肽类似物
US9840555B2 (en) * 2013-11-04 2017-12-12 Li-Te Chin Method for producing human monoclonal antibodies that binds to at least one part of HMGB1
CU20140026A7 (es) 2014-03-03 2015-11-27 Ct De Ingeniería Genética Y Biotecnología Biocubafarma Péptidos horquilla beta con propiedades antivirales contra el virus dengue

Similar Documents

Publication Publication Date Title
JP2019523633A5 (https=)
AU2022200946B2 (en) Modulators of the integrated stress pathway
JP2016531105A5 (https=)
AU2020281003B2 (en) Process for preparing an anti-cancer agent, 1-((4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl) cyclopropanamine, its crystalline form and its salts
US10300051B2 (en) Cyclopropylamines as LSD1 inhibitors
ES2718409T3 (es) Síntesis de compuestos de carbomoilpiridona policíclica
ES2690082T3 (es) Derivados de purina para el tratamiento de infecciones virales
JP2021524838A5 (https=)
CN107922387B (zh) Erk1与erk2的杂环抑制剂及其在癌症治疗中的应用
ES2709975T3 (es) Compuestos inmunomoduladores y antiinflamatorios novedosos
BR112020006780A2 (pt) moduladores do estimulador de genes do interferon (sting)
ES2499028T3 (es) Derivados de anilino-pirimidina sustituidos con sulfoximina como inhibidores de CDK, su preparación y uso como medicamentos
US20210032244A1 (en) Cyclopropylamines as lsd1 inhibitors
ES2805835T3 (es) Compuestos policíclicos como inhibidores de quinasa de tirosina de Bruton
KR20180124149A (ko) 단백질 조정제로서 유용한 헤테로시클릭 아미드
RU2014121073A (ru) Бициклические соединения пиперазина
CN107735401B (zh) 取代二氢吡咯并吡唑衍生物
AU2013326429B2 (en) N-prop-2-ynyl carboxamide derivatives and their use as TRPA1 antagonists
SA515360611B1 (ar) مشتقات كلورو-بيرازين كربوكساميد مفيدة لعلاج أمراض مصحوبة بترطيب مخاطي غير كافي
US10987349B2 (en) Antitumor agent and bromodomain inhibitor
WO2009067856A1 (fr) Inhibiteur de l'histone désacétylase, composition et utilisation de celui-ci
WO2019100061A1 (en) Oxoacridinyl acetic acid derivatives and methods of use
JP6262363B2 (ja) ブロモドメイン阻害剤としてのキノリン誘導体
ES2963447T3 (es) Nuevos procesos e intermediarios para la preparación de estimulantes de guanilato ciclasa soluble
Kaur et al. Synthesis and studies of new purines/pyrimidine derivatives as multi-targeted agents involving various receptor sites in the immune system